Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS

Nature Reviews Drug Discovery

Volumn 16, Issue 1, 2016, Pages 1-2

  Artigas, Francesc ^a,b,c   Schenker, Esther ^d   Celada, Pau ^a,b,c   Spedding, Michael ^d   Lladó Pelfort, Laia ^a,b,c   Jurado, Noemi ^a,b,c   Núñez, Mercedes ^a,b,c   Santana, Noemi ^a,b,c   Troyano Rodriguez, Eva ^a,b,c   Riga, Maurizio S ^a,b,c   van den Munkhof, Hanna ^a,b,c   Castañé, Anna ^a,b,c   Shaban, Hamdy ^e,f   Jay, Thérèse M ^g   Tripathi, Anushree ^g   Godsil, Bill P ^g   Sebban, Claude ^h   Mariani, Jean ^h   Faure, Philippe ^h   Takkilah, Samir ^h   Hughes, Zoe A ⁱ   Siok, Chester J ⁱ   Hajos, Mihaily ⁱ   Wicke, Karsten ^j   Gass, Natalia ^k   Weber Fahr, Wolfgang ^k   Sartorius, Alexander ^k   Becker, Robert ^k   Didriksen, Michael ^l   Bastlund, Jesper F ^l   Tricklebank, Mark ^m   Risterucci, Céline ⁿ   Meyer Lindenberg, Andreas ^k   Schwarz, Adam J ^m   more..

^a CSIC   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d INSTITUT DE RECHERCHES SERVIER   (France)

^e SPEDDING RESEARCH SOLUTIONS SARL   (France)

^f JANSSEN RESEARCH FOUNDATION   (Belgium)

^g CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ PFIZER INC   (United States)

^j ABBVIE INC   (United States)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l H LUNDBECK A S   (Denmark)

^m ELI LILLY AND COMPANY   (United States)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

BEHAVIOR ASSESSMENT; BRAIN ELECTROPHYSIOLOGY; CLINICAL RESEARCH; CONNECTOME; CONNECTOPATHY; COPY NUMBER VARIATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEALTH CARE NEED; HUMAN; MENTAL DISEASE; NEUROIMAGING; NEUROPATHY; NONHUMAN; NOTE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; THALAMOCORTICAL TRACT; DEPRESSIVE DISORDER; DRUG INDUSTRY; NERVE TRACT; PATHOPHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; DRUG INDUSTRY; HUMANS; MENTAL DISORDERS; NEURAL PATHWAYS; SCHIZOPHRENIA;

EID: 84994085933     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.205     Document Type: Note

References (5)

1. Godsil B. P, et al. The hippocampal-prefrontal pathway: the weak link in psychiatric disorders? Eur. Neuropsychopharmacol. 23, 1165-1181 (2013).
2. Troyano-Rodríguez E, et al. Phencyclidine inhibits the activity of thalamic reticular gamma-Aminobutyric acidergic neurons in rat brain. Biol. Psychiatry 76, 937-945 (2014).
3. Santana N, et al. Activation of thalamocortical networks by the N-methyl-d-Aspartate receptor antagonist phencyclidine: reversal by clozapine. Biol. Psychiatry 69, 918-927 (2011).
4. Lladó-Pelfort L, et al. Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: effects of antipsychotic drugs and receptor ligands. Eur. Neuropsychopharmacol. 26, 614-625 (2016).
5. Grimm O, et al. Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology 232, 4231-4241 (2015).